Skip to main
WVE

WVE Stock Forecast & Price Target

WVE Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

WAVE Life Sciences is a promising biotechnology company with a strong RNA medicines platform that combines multiple modalities to treat rare and prevalent diseases. A recent POC study showed positive effects on visceral fat reduction and cardiometabolic markers, validating the potential of their obesity drug, WVE-007. Additionally, partnerships with GSK for its AATD drug and potential for accelerated approval for its DMD drug provide a strong financial outlook for the company.

Bears say

WAVE Life Sciences is a clinical-stage biotechnology company with an ambitious goal of unlocking the potential of RNA medicines to transform human health. However, the company's current focus on the rare and prevalent diseases has led to concerns about its pipeline's sustainability and the potential for failure in clinical studies and securing regulatory approval. Additionally, the company's proprietary RNA-targeting modalities, while innovative, may not be as effective or specific as other approaches in the market, leading to concerns about their overall potential and commercial viability.

WVE has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Wave Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Wave Life Sciences (WVE) Forecast

Analysts have given WVE a Buy based on their latest research and market trends.

According to 14 analysts, WVE has a Buy consensus rating as of May 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Wave Life Sciences (WVE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.